All

MediGence Receives Key Temos Certification for Upholding International Quality Standards for Medical Travel

  • by

The global medical tourism platform MediGence proudly announces the addition of the accreditation of “Quality in International Medical Travel Coordination” from the global leader Temos International. MediGence becomes the first medical travel coordinator in India to achieve Temos certification for its unmatched services to international… Read More »MediGence Receives Key Temos Certification for Upholding International Quality Standards for Medical Travel

Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020

  • by

Shots: The company presented the new data of its T-cell engaging bispecific Abs, mosunetuzumab, glofitamab and cevostamab at ASH 2020, demonstrating encouraging activity across multiple types of blood cancer Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL, including… Read More »Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020

Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib)

  • by

Shots: The US FDA approved FoundationOneCDx to be used as a CDx for Vitrakvi (larotrectinib) to identify patients with NTRK fusions across all solid tumors. The genomic test is currently approved as a CDx for 20+ therapies The FoundationOne CDx is the tissue-based CGP test… Read More »Foundation Medicine’s FoundationOne CDx Receives the US FDA’s Approval as a CDx for Vitrakvi (larotrectinib)

Roche Reports the US FDA’s Acceptance of sBLA for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications

  • by

Shots: The US FDA has accepted the sBLA for a new self-administration option for Xolair across all approved indications in the US. The company anticipates the approval of the therapy in Q1’21 The acceptance is based on the efficacy and safety profile of Xolair in… Read More »Roche Reports the US FDA’s Acceptance of sBLA for Xolair (omalizumab) Prefilled Syringe for Self-Administration Across All Indications